Wall Street Zen Downgrades Adaptive Biotechnologies (NASDAQ:ADPT) to Hold

Adaptive Biotechnologies (NASDAQ:ADPT) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Guggenheim upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their price objective on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus target price of $17.22.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock opened at $18.50 on Friday. Adaptive Biotechnologies has a fifty-two week low of $6.26 and a fifty-two week high of $20.76. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -34.26 and a beta of 2.18. The stock has a 50 day moving average of $17.29 and a 200 day moving average of $14.97.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. The business had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company’s quarterly revenue was up 102.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.22) EPS. Analysts forecast that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, insider Harlan S. Robins sold 10,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the transaction, the insider directly owned 1,222,312 shares of the company’s stock, valued at $20,094,809.28. The trade was a 0.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Francis Lo sold 79,590 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $17.73, for a total value of $1,411,130.70. Following the sale, the insider owned 315,978 shares in the company, valued at approximately $5,602,289.94. This trade represents a 20.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,442,530 shares of company stock valued at $24,610,748. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently made changes to their positions in ADPT. AQR Capital Management LLC raised its holdings in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after acquiring an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at approximately $93,000. KLP Kapitalforvaltning AS raised its holdings in shares of Adaptive Biotechnologies by 42.9% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 25,000 shares of the company’s stock valued at $291,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Adaptive Biotechnologies by 9.9% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 32,038 shares of the company’s stock worth $373,000 after purchasing an additional 2,880 shares during the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.